A new type of pterocarpanquinone that affects Toxoplasma gondii tachyzoites in vitro

Veterinary Parasitology

Volumn 186, Issue 3-4, 2012, Pages 261-269

  Portes, Juliana de Araujo ^a   Netto, Chaquip Daher ^b   da Silva, Alcides José Monteiro ^b   Costa, Paulo Roberto Ribeiro ^b   DaMatta, Renato Augusto ^c   Santos, Thiago Alves Teixeira dos ^a   De Souza, Wanderley ^b   Seabra, Sergio Henrique ^a  

^a Brasil   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE DARCY RIBEIRO   (Brazil)

Author keywords

Anti proliferative activity; Chemotherapy; New pterocarpanquinone derivative; Toxoplasma gondii; Ultrastructure

Indexed keywords

ANTIPARASITIC AGENT; BAG 1 PROTEIN; LECTIN; PTEROCARPANQUINONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BRADYZOITE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DOLICHOS; DOLICHOS BIFLORUS; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; IC 50; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MOLECULAR HYBRIDIZATION; MOUSE; NONHUMAN; PARASITE IDENTIFICATION; PARASITE SURVIVAL; PROTEIN EXPRESSION; RHESUS MONKEY; SCANNING TRANSMISSION ELECTRON MICROSCOPY; TACHYZOITE; TOXOPLASMA GONDII;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; MACACA MULATTA; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR STRUCTURE; PTEROCARPANS; TOXOPLASMA;

DOLICHOS BIFLORUS; LEISHMANIA AMAZONENSIS; PLASMODIUM FALCIPARUM; PROTOZOA; TOXOPLASMA GONDII; VERTEBRATA;

EID: 84860261029     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2011.11.008     Document Type: Article

References (25)

1. Cammerer S.B., Jimenez C., Jones S., Gros L., Lorente S.O., Rodrigues C., Rodrigues J.C.F., Caldera A., Perez L.M.R., De Souza W., Kaiser M., Brun R., Urbina J.A., Pacanowska D.G., Gilbert I.H. Quinuclidine derivatives as potential antiparasitics. Antimicrob. Agents Chemother. 2007, 51:4049-4061.
2. Chen Y., Hu L. Design of anticancer prodrugs for reductive activation. Med. Res. Rev. 2009, 29:29-64.
3. Da Silva A.J.M., Buarque C.D., Brito F.V., Aurelian L., Macedo L.F., Malkas L.H., Hickey R.J., Lopes D.V.S., Noel F., Yugo L.B.M., Silva N.M.V., Melo P.A., Caruso R.R.B., Castro N.G., Costa P.R. Synthesis and preliminary pharmacological evaluation of new (±) 1,4-naphthoquinones structurally related to lapachol. Bioorg. Med. Chem. 2002, 10:2731-2738.
4. Da Silva A.J.M., Netto C.D., Lima W.P., Santos E.C.T., Bergmann B.R., Maruel S., Valentin A., Costa P.R. Antitumoral, antileishmanial and antimalarial activity of pentacyclic 1,4-naphthoquinone derivatives. J. Braz. Chem. Soc. 2009, 20:176-182.
5. De Souza W., Duarte E.S.M., Urbina J.A., Vommaro R.C. Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro. J. Antimicrob. Chemother. 2006, 58:59-65.
6. Djakovic O.D., Nikolic A., Bobic B., Klun I., Aleksic A. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate. Microbes Infect. 2005, 7:49-54.
7. Galm U., Hager M.H., Lanen S.G.V., Ju J., Thorson J.S., Shen B. Antitumor antibiotics: bleomycin, enediynes, and mitomycin. Chem. Rev. 2005, 105:739-758.
8. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracyclines antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
9. Haverkos H.W. Assessment of therapy for Toxoplasma Encephalitis. The TE study group. Am. J. Med. 1987, 82:907-914.
10. Levine N.D., Corliss J.O., Cox F.E.G., Deroux G., Grain J., Honigberg B.M., Leedale G.F., Loeblich A.R., Lom J., Lynn D., Merinfeld E.G., Page F.C., Poljansky G., Sprague V., Vavra J., Wallace F.G. A newly revised classification of the Protozoa. J. Protozool. 1980, 27:37-58.
11. Linardi M.C.F., de Oliveira M.M., Sampaio M.R.P. A lapachol derivative active against mouse lymphocytic leukemia P-388. J. Med. Chem. 1975, 18:1159-1161.
12. Lyons R.E., Johnson A.M. Heat shock proteins of Toxoplasma gondii. Parasite Immunol. 1995, 17:353-359.
13. Magno R.C., Lemgruber L., Vommaro R.C., De Souza W., Attias M. Intravacuolar network may act as a mechanical support for Toxoplasma gondii inside the parasitophorous vacuole. Microsc. Res. Tech. 2005, 67:45-52.
14. McAllister M.M., Parmley S.F., Weiss L.M., Welch V., McGuire A.M. An immunohistochemical method for detecting bradyzoite antigen (BAG5) in Toxoplasma gondii infected tissues cross reacts with a Neospora caninum bradyzoite antigen. Protozoology 1995, 82:354-355.
15. Mcauley J., Boyer K.M., Patel D., Mets M., Swisher C., Roizen N., Wolters C., Stein L., Stein M., Schey W., Remington J., Meier P., Johnson D., Heydeman P., Holfels E., Withers S., Mack D., Brown C., Patton D., McLeod R. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital Toxoplasmosis: the Chicago collaborative treatment trial. Clin. Infect. Dis. 1994, 18:38-72.
16. Molina Portela M.P., Stoppani A.O. Redox cycling of beta-lapachone and related o-naphthoquinones in the presence of dihydrolipoamide and oxygen. Biochem. Pharmacol. 1996, 51:275-283.
17. Netto C.D., Da Silva A.J., Salustiano E.J., Bacelar T.S., Riça I.G., Cavalcante M.C., Rumjanek V.M., Costa P.R. New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-a modulation in human PBMC cells. Bioorg. Med. Chem. 2010, 18:1610-1616.
18. O'Brien P.J. Molecular mechanisms of quinone cytotoxicity. Chem. Biol. Interact. 1991, 80:1-41.
19. Salas C., Tapia R.A., Ciudad K., Armstrong V., Orellana M., Kemmerling U., Ferreira J., Maya J.D., Morello A. Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms. Bioorg. Med. Chem. 2008, 16:668-674.
20. Saleh A., Friesen J., Baumeister S., Gross U., Bohne W. Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1h)quinolone, a high-affinity inhibitor of alternative (type I) NADH dehydrogenases. Antimicrob. Agents Chemother. 2007, 51:1217-1222.
21. Salustiano E.J., Netto C.D., Fernandes R.F., Da Silva A.J., Bacelar T.S., Castro C.P., Buarque C.D., Maia R.C., Rumjanek V.M., Costa P.R. Comparison of the cytotoxic effect of lapachol, α-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells Invest. New Drugs 2009, 28:139-144.
22. Villard O., Candolfi E., Ferguson D.J.P., Marcellin L., Kien T. Loss of oral infectivity of tissue cysts of Toxoplasma gondii RH strain to outbred Swiss-Webster mice. Int. J. Parasitol. 1997, 27:1555-1559.
23. Wolkenberg S.E., Boger D.L. Mechanisms of in situ activation for DNA-targeting antitumor agents. Chem. Rev. 2002, 102:2477-2496.
24. Zhang Y.W., Halonen S.K., Ma Y.F., Wittner M., Weiss L.M. Initial characterization of CST1, a Toxoplasma gondii cyst wall glycoprotein. Infect. Immun. 2001, 69:501-507.
25. Zhang G., Fang L., Zhu L., Zhong Y., Wang P.G., Sun D. Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia. J. Med. Chem. 2006, 49:1792-1799.